201 related articles for article (PubMed ID: 1544831)
1. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Walton MI; Sugget N; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
[TBL] [Abstract][Full Text] [Related]
2. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
Walton MI; Smith PJ; Workman P
Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
Bailey SM; Suggett N; Walton MI; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
[TBL] [Abstract][Full Text] [Related]
4. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
Plumb JA; Workman P
Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
[TBL] [Abstract][Full Text] [Related]
5. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
Plumb JA; Gerritsen M; Workman P
Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885
[TBL] [Abstract][Full Text] [Related]
6. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.
Bailey SM; Wyatt MD; Friedlos F; Hartley JA; Knox RJ; Lewis AD; Workman P
Br J Cancer; 1997; 76(12):1596-603. PubMed ID: 9413948
[TBL] [Abstract][Full Text] [Related]
7. Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells.
Riley RJ; Workman P
Biochem Pharmacol; 1992 Jan; 43(2):167-74. PubMed ID: 1739405
[TBL] [Abstract][Full Text] [Related]
8. Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites.
Bailey SM; Lewis AD; Knox RJ; Patterson LH; Fisher GR; Workman P
Biochem Pharmacol; 1998 Sep; 56(5):613-21. PubMed ID: 9783730
[TBL] [Abstract][Full Text] [Related]
9. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
[TBL] [Abstract][Full Text] [Related]
10. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH
Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024
[TBL] [Abstract][Full Text] [Related]
11. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
12. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) by purified DT-diaphorase under aerobic and anaerobic conditions.
Cahill A; Jenkins TC; White IN
Biochem Pharmacol; 1993 Jan; 45(2):321-9. PubMed ID: 7679576
[TBL] [Abstract][Full Text] [Related]
14. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
15. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas.
Walton MI; Bibby MC; Double JA; Plumb JA; Workman P
Eur J Cancer; 1992; 28A(10):1597-600. PubMed ID: 1389472
[TBL] [Abstract][Full Text] [Related]
16. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
Walton MI; Workman P
Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
18. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide).
Boland MP; Knox RJ; Roberts JJ
Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):867-75. PubMed ID: 1901207
[TBL] [Abstract][Full Text] [Related]
19. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.
Bailey SM; Lewis AD; Patterson LH; Fisher GR; Knox RJ; Workman P
Biochem Pharmacol; 2001 Aug; 62(4):461-8. PubMed ID: 11448456
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.
Robertson N; Haigh A; Adams GE; Stratford IJ
Eur J Cancer; 1994; 30A(7):1013-9. PubMed ID: 7946565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
